No Data
No Data
GeneDx Continues Its Leadership in Genomics Research, Refining Gene-Disease Relationships and Impacting Results of >22,000 Patients
GeneDx Holdings Is Maintained at Buy by TD Cowen
GeneDx Hldgs Analyst Ratings
TD Cowen Maintains GeneDx Holdings(WGS.US) With Buy Rating, Raises Target Price to $118
GeneDx Holdings (WGS) Surges 13.2%: Is This an Indication of Further Gains?
Trending Stocks Today | MultiSensor AI Shoots up 38% Post-Market